US investment firm obtains 26pc interest in State-backed Malin
US private investment firm Pentwater Capital Management has obtained a 26pc interest in State-backed life science investor Malin.
Pentwater has been a shareholder of Malin for nearly two years but has increased its interest by approximately 23pc in recent weeks.
The group is also an investor in a number of healthcare companies, including Poseida, Autolus, Spark Therapeutics, Esperion Therapeutics.
This investment in Malin is held through various counterparties.
Other major shareholders in Malin include the State's Ireland Strategic Investment Fund.
Liam Daniel, chairman of Malin, said the group “welcomed” Pentwater as significant stakeholders.
"Our assets are progressing, with several significant near-term milestones which I believe can be the catalysts to significant value creation for all our shareholders," he said.
Earlier this year embattled fund manager Neil Woodford sold all of his firm's stake in the Irish life sciences investment firm.
Woodford Investment Management held a near 23pc stake in Malin prior to the share sale.